iRhythm Holdings, Inc.IRTC

iRhythm Holdings’ latest 10-Q lands with the quiet thud of a company that talks a big game in AI-driven cardiac monitoring but still can’t escape the basic arithmetic of cash burn. For the quarter ended March 31, 2026, revenue clocked in at $199.4 million, yet net income slid to a loss of $13.9 million, while operating loss widened to $16.2 million. Cash used in operations hit $26.2 million, all while inventory crept up by $2.4 million to $23.8 million and capex gobbled $6.9 million. The balance sheet still cushions the fall with $240.1 million in cash, but equity has been whittled down to $161.2 million against $845.2 million in liabilities-hardly the stuff of a business basking in AI glory.

What iRhythm actually sells is the Zio ECG monitoring service: up to 14 days of continuous rhythm capture, backed by FDA-cleared AI the company claims is as accurate as cardiologists, delivered via remote enrollment, telehealth workflows, and EHR integration. The product pages are polished, the clinical references are on file, and the company markets precision, low retest rates, and 99% physician agreement. The marketing story is neat; the cash-flow story is less so. The company’s own data sheets and reference manuals tout the diagnostic yield and physician agreement, but the 10-Q quietly records the financial cost of that precision.

Filing facts for the quarter are unambiguous: revenue of $199.4 million, net loss of $13.9 million, operating loss of $16.2 million, diluted EPS of -$0.43 on 32.5 million shares, cash used in operations of $26.2 million, capex of $6.9 million, inventory at $23.8 million with a $2.4 million increase, cash and equivalents at $240.1 million, total assets at $1.01 billion, liabilities at $845.2 million, and stockholders’ equity at $161.2 million. The 10-Q for the period ending March 31, 2026 is the primary source for all these figures.

This is a medical device company whose public materials read like a Silicon Valley pitch deck-FDA-cleared AI, remote monitoring, EHR integration-yet its regulatory filings tell a quieter tale of cash burn, inventory build, and thin equity. The product is real, the clearances are real, and the integration claims are supported by named workflows, but the financial reality is still catching up with the marketing narrative. The company’s own website and clinical reference manuals substantiate the product claims, while the 10-Q substantiates the cash reality.

The company has yet to file an 8-K or 10-Q that includes explicit guidance or a segment split that would clarify where growth is strongest or where the cash burn might stabilise. The most recent governance note is the May 27, 2026 annual meeting, where shareholders approved a tweak to the certificate of incorporation to remove a pass-through voting provision-an internal governance move that does not address the company’s cash runway. Insider trading activity is documented in Form 4 filings, but those disclosures do not alter the financial trajectory.

What would change the file? A quarterly update that shows operating cash flow turning positive, inventory growth flattening, and guidance that implies a path to GAAP profitability within the next four quarters. Until then, iRhythm’s story remains a fascinating collision of FDA-cleared AI and GAAP red ink-slick enough to sell to clinicians, but still too expensive to love on the balance sheet.